Cochlear Trims Dividend as Hearing Implant Profit Falls

Cochlear cut its annual dividend 20% to A$3.45 per share as FY26 hearing implant profit slid 22%, yet COH shares rallied ~7% on results landing at the top of revised guidance.

FY26 underlying net profit fell 22% to A$322 million, reaching the upper bound of Cochlear's twice-revised guidance range.
The annual dividend was reduced to A$3.45 per share from A$4.30, the steepest single-year cut in at least four years.
COH and CSL together pushed the S&P/ASX 200 0.2% higher to 9,062.60 on 18 August 2026.

Lead

Cochlear Limited (COH) reported fiscal 2026 underlying net profit of A$322 million, down 22%, and declared a final ordinary dividend of A$1.30 per share (85% franked), bringing the full-year payout to A$3.45 - a 20% reduction from the A$4.30 paid in FY25. Revenue reached A$2.343 billion, a 2% gain in constant currency, as hearing implant unit shipments rose 5% to 56,692. The Sydney-based company's results landed at the top of heavily downgraded guidance issued in April, and COH shares climbed approximately 7% on 18 August, contributing to a healthcare-led rally that lifted the market index ASX 200 to 9,062.60, up 0.2% for the session.

Why Did Cochlear Cut Its Dividend?

The reduction follows directly from Cochlear's policy of paying 70% of underlying net profit, meaning lower earnings mechanically produce lower distributions. The A$1.30 final dividend compares with A$2.15 the prior year. Total annual payments have now retreated from A$4.30 in FY25 and A$4.10 in FY24 to A$3.45 in FY26, with management signaling no near-term restoration of pre-2026 payout levels until operating conditions stabilize. The currency drag of approximately A$25 million after tax compounded the pressure on the earnings base that drives the payout calculation.

What Drove the Profit Decline?

Gross margins narrowed from 74% to 71%, the primary source of the earnings shortfall. A shift toward lower-priced units in emerging markets - particularly China and the Middle East, where reimbursement structures cap revenue per device - diluted the overall yield even as shipment volumes expanded. Manufacturing variances added incremental cost pressure. Middle East order cancellations and softer Chinese reimbursement rates trimmed the top line, while the strengthening Australian dollar eroded the translated value of foreign-currency revenues.

Cochlear had already cut full-year guidance twice before August, most sharply in April 2026 when it reduced the profit outlook from A$435 million-A$460 million to A$290 million-A$330 million - a roughly 30% downgrade at the midpoint that sent COH to a decade low near A$102. The August print of A$322 million, at the top of the revised range, reassured investors that the deterioration had been fully quantified.

How Did Healthcare Stocks Shape the Sydney Exchange?

The healthcare sector rose 7.3% on 18 August, the strongest sector gain of the session. CSL Limited (CSL) led the advance, surging 17.3% to A$157.94 - its highest level in six months - after reporting FY26 revenue of US$15.8 billion and underlying profit of US$3.1 billion. A statutory loss of US$2.58 billion, CSL's first annual loss as a listed company, reflected large non-cash impairment charges rather than operational deterioration, and investors moved past the headline figure to focus on the underlying business recovery.

The combined index weight of COH and CSL was sufficient to offset selling in consumer staples (-1.3%), telecommunications (-1.2%), and financials (-1.1%), leaving the S&P/ASX 200 0.2% higher at 9,062.60.

Nexa Launch and FY27 Priorities

Cochlear's near-term growth thesis centers on the Nucleus Nexa, a next-generation cochlear implant system entering commercial rollout in FY27. Management described the product as central to recapturing premium pricing in the United States and Europe, where constrained surgical volumes had limited revenue growth. The company is also investing in referral-pathway programs designed to identify and route untreated hearing-loss patients toward implantation, a strategy aimed at broadening the addressable market beyond existing procedure-capacity constraints.

Outlook

Cochlear enters FY27 targeting profit growth off the FY26 base, contingent on the Nexa commercial launch, a recovery in developed-market surgical volumes, and stabilization of the Australian dollar against key billing currencies. CSL's guidance for continued double-digit underlying earnings growth adds further ballast to the healthcare sector on the Sydney exchange. Sustained recovery for Cochlear will depend on Chinese and Middle Eastern reimbursement policy, manufacturing cost normalization, and the rate at which Nexa gains clinical adoption across key developed-market hospital systems.